Anzeige
Mehr »
Login
Samstag, 11.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Innocan Pharma News: Unfassbare Studie - LPT-Therapie bewahrt Patient vor dem Tod!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D4GD | ISIN: US02155X2053 | Ticker-Symbol: PBN0
Siehe auch ALTERITY THERAPEUTICS LIMITED
München
10.05.24
08:03 Uhr
1,960 Euro
-0,010
-0,51 %
Branche
Biotechnologie
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
ALTERITY THERAPEUTICS LIMITED ADR Chart 1 Jahr
5-Tage-Chart
ALTERITY THERAPEUTICS LIMITED ADR 5-Tage-Chart
RealtimeGeldBriefZeit
1,5202,16010.05.

Aktuelle News zur ALTERITY THERAPEUTICS LIMITED ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer-
MiALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review33- ATH434-201 Trial on Track to Complete in November 2024 - - Top-Line Data Expected in January 2025 - MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics...
► Artikel lesen
DiALTERITY THERAPEUTICS LIMITED: Phase 2 DMC Recommends Continuing Clinical Trial as Planned-
DiALTERITY THERAPEUTICS LIMITED: Ceasing to be a substantial holder-
02.05.ALTERITY THERAPEUTICS LIMITED: Change in substantial holding-
30.04.ALTERITY THERAPEUTICS LIMITED: Appendix 4C - Q3 FY24 Quarterly Cash Flow Report75Highlights ATH434-201 Phase 2 baseline data confirm approach to target biomarkers for slowing disease progressionPresented promising nonclinical data on ATH434 in a primate model of Parkinson's diseaseRaised...
► Artikel lesen
30.04.ALTERITY THERAPEUTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report-
29.04.ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia1
29.04.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer-
29.04.ALTERITY THERAPEUTICS LIMITED: Application for quotation of securities - ATH-
28.04.ALTERITY THERAPEUTICS LIMITED: Alterity Presents New Data on ATH434-
17.04.ALTERITY THERAPEUTICS LIMITED: Change in substantial holding1
17.04.ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting83- ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson's Disease - - ATH434-201 Phase 2 Baseline Data Confirm Approach to Target Biomarkers for Slowing Disease...
► Artikel lesen
16.04.ALTERITY THERAPEUTICS LIMITED: Alterity Parkinson's and MSA Data Featured at AAN Meeting-
15.04.ALTERITY THERAPEUTICS LIMITED: Application for quotation of securities - ATH1
12.04.CERS, GL and ATHE are among pre market gainers2
12.04.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer2
12.04.ALTERITY THERAPEUTICS LIMITED: Options Prospectus1
12.04.ALTERITY THERAPEUTICS LIMITED: Results of Extraordinary General Meeting-
11.04.ATUS, ATHE and GRFS among pre-market losers1
Seite:  Weiter >>
138 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1